scholarly journals Producing Omega-3 Polyunsaturated Fatty Acids: A Review of Sustainable Sources and Future Trends for the EPA and DHA Market

Resources ◽  
2020 ◽  
Vol 9 (12) ◽  
pp. 148
Author(s):  
Laura Oliver ◽  
Thomas Dietrich ◽  
Izaskun Marañón ◽  
Maria Carmen Villarán ◽  
Ramón J. Barrio

Omega-3 polyunsaturated fatty acids (Omega-3 PUFA) are recognized as being essential compounds for human nutrition and health. The human body generates only low levels of Omega-3 PUFA. Conventional sources of Omega-3 PUFA are from marine origin. However, the global growth of population combined with a better consumer understanding about healthy nutrition leads to the fact that traditional sources are exhausted and therefore not enough to satisfy the demand of Omega-3 PUFA for human diet as well as aquaculture. Microalgae cultivated under heterotrophic conditions is increasingly recognized as a suitable technology for the production of the Omega-3 PUFA. The high cost of using glucose as main carbon source for cultivation is the main challenge to establish economical feasible production processes. The latest relevant studies provide alternative pathways for Omega-3 PUFA production. As preliminary results show, volatile fatty acids (VFA) recovered from waste stream could be a good alternative to the use of glucose as carbon source in microalgae cultivation. The purpose of this paper is to highlight the actual situation of Omega-3 PUFA production, sources and market request to provide a summary on sustainable sources that are being investigated as well as present and future market trends in Omega-3 market.

2020 ◽  
Vol 10 (6) ◽  
pp. 381
Author(s):  
Mayra Montecillo-Aguado ◽  
Belen Tirado-Rodriguez ◽  
Zhen Tong ◽  
Owen M. Vega ◽  
Mario Morales-Martínez ◽  
...  

Brain cancer is one of the most malignant types of cancer in both children and adults. Brain cancer patients tend to have a poor prognosis and a high rate of mortality. Additionally, 20–40% of all other types of cancer can develop brain metastasis. Numerous pieces of evidence suggest that omega-3-polyunsaturated fatty acids (ω-PUFAs) could potentially be used in the prevention and therapy of several types of cancer. PUFAs and oxylipins are fundamental in preserving physiological events in the nervous system; it is, therefore, necessary to maintain a certain ratio of ω-3 to ω-6 for normal nervous system function. Alterations in PUFAs signaling are involved in the development of various pathologies of the nervous system, including cancer. It is well established that an omega-6-polyunsaturated fatty acid (ω-6 PUFA)-rich diet has a pro-tumoral effect, whereas the consumption of an ω-3 rich diet has an anti-tumoral effect. This review aims to offer a better understanding of brain cancer and PUFAs and to discuss the role and impact of PUFAs on the development of different types of brain cancer. Considering the difficulty of antitumor drugs in crossing the blood–brain barrier, the therapeutic role of ω-3/ω-6 PUFAs against brain cancer would be a good alternative to consider. We highlight our current understanding of the role of PUFAs and its metabolites (oxylipins) in different brain tumors, proliferation, apoptosis, invasion, angiogenesis, and immunosuppression by focusing on recent research in vitro and in vivo.


2020 ◽  
Vol 36 (2) ◽  
pp. 95-106
Author(s):  
Agnieszka M. Piróg-Balcerzak ◽  
Anna K. Bażyńska ◽  
Katarzyna Biernacka ◽  
Joanna Brągoszewska ◽  
Lidia Popek ◽  
...  

Objective. Omega–3 polyunsaturated fatty acids (PUFAs) were tested in adolescent depression and in several neurodevelopmental disorders with partial success. Anorexia nervosa (AN) is characterised by deficiencies in fatty food intake and frequent comorbidity, including depressive and cognitive symptoms. Thus supplementation with PUFAs may be beneficial in this group of patients. The aim of the study was to assess whether PUFAs as an add-on treatment is associated with better improvement of body mass index (BMI) and psychopathological symptoms than placebo in patients with AN. Method. 61 female adolescent inpatients with AN were randomly allocated to omega–3 PUFAs supplementation or placebo for 10 weeks. Patients also participated in the behavioural programme and eclectic psychotherapy (treatment as usual, TAU). At baseline and follow-up visits, patients’ BMI and psychopathology were assessed with Clinical Global Impression Scale (CGI), Patient Global Impression Scale (PGI), and Eating Attitude Test (EAT-26). Results. After 10 weeks, both groups showed improvement in all parameters. Improvement in CGI scores was observed greater in placebo vs. PUFA-s group (p = 0.015) while other differences were not statistically significant. Omega–3 PUFAs supplementation appears not to be effective as an add-on treatment in inpatient adolescent girls with anorexia nervosa. Conclusions. The results should be analysed with caution due to small sample size and heterogeneity in TAU. As the TAU turned out to be highly effective, additional therapeutic effect of PUFA might not be visible. Nevertheless, that does not explain the tendency for better improvement in the placebo group.


2013 ◽  
Vol 13 (8) ◽  
pp. 1162-1177 ◽  
Author(s):  
Kaipeng Jing ◽  
Tong Wu ◽  
Kyu Lim

2021 ◽  
pp. 101276
Author(s):  
Sang Hyeok Lee ◽  
Yoo Bhin Kim ◽  
Da-Hye Kim ◽  
Dong-Won Lee ◽  
Hong-Gu Lee ◽  
...  

Redox Biology ◽  
2021 ◽  
pp. 102061
Author(s):  
Lucía Fernández-del-Río ◽  
Sandra Rodríguez-López ◽  
Elena Gutiérrez-Casado ◽  
José Antonio González-Reyes ◽  
Catherine F. Clarke ◽  
...  

2021 ◽  
Vol 35 (3) ◽  
pp. 221-235
Author(s):  
Kah K Goh ◽  
Cynthia Yi-An Chen ◽  
Chun-Hsin Chen ◽  
Mong-Liang Lu

Background: Several monotherapy and augmentation strategies have been introduced to improve the treatment of schizophrenia. The benefits of omega-3 polyunsaturated fatty acids in patients with mental disorders is becoming increasingly acknowledged. However, its role in the treatment of schizophrenia raises complex considerations about which there has been little consensus. The aim of this study was to synthesize the findings of randomized controlled trials that were conducted to determine the efficacy and safety of omega-3 polyunsaturated fatty acids in patients with schizophrenia. Methods: The MEDLINE, Embase, Cochrane, Scopus, and Web of Science databases were searched for relevant literature. The primary outcome was changes in psychopathology and the secondary outcomes were changes in metabolic parameters and safety profiles. Results: Twenty double-blind randomized controlled trials in 1494 patients were included. Omega-3 polyunsaturated fatty acids augmentation was associated with significantly improved psychopathology in patients with schizophrenia, particularly general psychopathology and positive symptoms but not negative symptoms. Patients who were severely ill and received omega-3 polyunsaturated fatty acids containing eicosapentaenoic acid >1 g/d showed significant improvement. A favorable effect of omega-3 polyunsaturated fatty acids supplements on serum triglycerides was also demonstrated. Omega-3 polyunsaturated fatty acids are well-tolerated and safe in patients with schizophrenia. Conclusions: These findings tentatively support the use of omega-3 polyunsaturated fatty acids as a potential augmentation strategy in schizophrenia. Further research in larger samples is warranted to clarify the optimal dosage and the correct proportions of omega-3 polyunsaturated fatty acids to administer, together with elucidation of the underlying mechanisms.


Sign in / Sign up

Export Citation Format

Share Document